7-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one | 1008798-54-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 7-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one
• CAS: 1008798-54-6
• 化学式: C₂₇H₂₈N₂O₃
• 分子量: 428.531
• InChiKey: HHLNQEVGHQDXJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  32.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  68.7
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  7-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one 、 3,5-difluorocinnamic acid 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-7-yloxy)ethyl]-3-(3,5-difluorophenyl)acrylamide
  参考文献：
  名称：

  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

  摘要：

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.09.100
• 作为产物：
  描述：

  2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-7-yloxy)ethylcarbamic acid tert-butyl ester 在 三氟乙酸 作用下， 以 氯仿 为溶剂， 反应 3.0h， 以78%的产率得到7-(2-aminoethoxy)-3-{4-[(benzylethylamino)methyl]phenyl}-chromen-2-one
  参考文献：
  名称：

  Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

  摘要：

  The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD. (c) 2007 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2007.09.100